Cargando…
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Ph...
Autores principales: | Clavreul, Anne, Pourbaghi-Masouleh, Milad, Roger, Emilie, Menei, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461002/ https://www.ncbi.nlm.nih.gov/pubmed/31040671 http://dx.doi.org/10.2147/IJN.S194858 |
Ejemplares similares
-
Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma
por: Clavreul, Anne, et al.
Publicado: (2018) -
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
por: Clavreul, Anne, et al.
Publicado: (2017) -
QCD at ATLAS: The Story So Far
por: Newman, Paul
Publicado: (2011) -
Biology Open: The story so far…
por: Raff, Jordan W., et al.
Publicado: (2015) -
Diet and Vitiligo: The Story So Far
por: Dutta, Rajoshee R, et al.
Publicado: (2022)